[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Design Therapeutics Inc (DSGN)

Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 849,198
  • Shares Outstanding, K 62,441
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,790 K
  • EBIT $ -79 M
  • EBITDA $ -82 M
  • 60-Month Beta 1.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.52

Options Overview Details

View History
  • Implied Volatility 140.25% (-4.82%)
  • Historical Volatility 87.08%
  • IV Percentile 9%
  • IV Rank 13.68%
  • IV High 469.08% on 11/13/25
  • IV Low 88.15% on 08/18/25
  • Expected Move (DTE 14) 0.31 (2.30%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 21
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 251
  • Open Int (30-Day) 143
  • Expected Range 12.99 to 13.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 3
  • High Estimate $-0.29
  • Low Estimate $-0.47
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) -5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.71 +24.19%
on 04/02/26
17.25 -22.90%
on 04/29/26
+2.29 (+20.80%)
since 04/01/26
3-Month
9.54 +39.46%
on 02/05/26
17.25 -22.90%
on 04/29/26
+3.09 (+30.26%)
since 01/30/26
52-Week
3.11 +328.34%
on 05/15/25
17.25 -22.90%
on 04/29/26
+8.59 (+182.38%)
since 05/01/25

Most Recent Stories

More News
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash...

DSGN : 13.30 (-2.21%)
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing...

DSGN : 13.30 (-2.21%)
Design Therapeutics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 13.30 (-2.21%)
Design Therapeutics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 13.30 (-2.21%)
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1)  Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs...

DSGN : 13.30 (-2.21%)
Design Therapeutics Appoints Justin Gover to Board of Directors

CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...

CMPS : 9.01 (-0.55%)
DSGN : 13.30 (-2.21%)
XENE : 56.13 (+0.16%)
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 13.30 (-2.21%)
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA...

DSGN : 13.30 (-2.21%)
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

DSGN : 13.30 (-2.21%)
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

DSGN : 13.30 (-2.21%)

Business Summary

Design Therapeutics Inc. is a biotechnology company. It involved in developing a platform of gene targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions. Design Therapeutics Inc. is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 14.87
2nd Resistance Point 14.41
1st Resistance Point 13.86
Last Price 13.30
1st Support Level 12.85
2nd Support Level 12.39
3rd Support Level 11.84

See More

52-Week High 17.25
Last Price 13.30
Fibonacci 61.8% 11.85
Fibonacci 50% 10.18
Fibonacci 38.2% 8.51
52-Week Low 3.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.